Nabriva Therapeutics (NASDAQ:NBRV) Share Price Passes Below 50-Day Moving Average of $1.89
Nabriva Therapeutics (NASDAQ:NBRV) Share Price Passes Below 50-Day Moving Average of $1.89
Shares of Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $1.89 and traded as low as $1.50. Nabriva Therapeutics shares last traded at $1.51, with a volume of 19,485 shares trading hands.
Analyst Ratings Changes
A number of equities analysts have issued reports on NBRV shares. StockNews.com assumed coverage on shares of Nabriva Therapeutics in a research report on Wednesday. They issued a "hold" rating on the stock. Northland Securities cut shares of Nabriva Therapeutics from an "outperform" rating to an "underperform" rating in a research report on Friday, January 6th.
Get Nabriva Therapeutics alerts:Nabriva Therapeutics Price Performance
The company has a quick ratio of 1.40, a current ratio of 2.20 and a debt-to-equity ratio of 0.02. The firm's 50-day moving average is $1.86 and its 200-day moving average is $3.58. The company has a market cap of $46.88 million, a PE ratio of -0.08 and a beta of 1.67.
Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) last announced its quarterly earnings results on Thursday, November 10th. The biotechnology company reported ($4.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.03) by ($0.18). Nabriva Therapeutics had a negative net margin of 133.25% and a negative return on equity of 120.02%. The company had revenue of $9.15 million for the quarter, compared to analysts' expectations of $10.68 million. On average, equities analysts anticipate that Nabriva Therapeutics plc will post -17.37 EPS for the current year.Institutional Investors Weigh In On Nabriva Therapeutics
An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC increased its holdings in shares of Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) by 102.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 795,938 shares of the biotechnology company's stock after acquiring an additional 402,144 shares during the period. Renaissance Technologies LLC owned approximately 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent reporting period. Institutional investors own 0.23% of the company's stock.
Nabriva Therapeutics Company Profile
(Get Rating)
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Featured Articles
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- Chevron Delights Shareholders with $75 Billion in Share Buybacks
- The Future Of E-Commerce: Analysis And New Data
- Levi Strauss Is A Good Fit For Income Investors
- 3 Small Caps That Have Big Upside
- Mullen Automotive: The Good News, The Bad And The Ugly Outlook
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
納布裡瓦治療公司(納斯達克代碼:nnrv-get評級)的股票在週二的交易中跌破了50日移動均線。該股的50日移動均線為1.89美元,交易價格低至1.50美元。Nabriva Treateutics的股票最後交易價格為1.51美元,成交量為19485股。
分析師評級發生變化
一些股票分析師已經發布了關於NBRV股票的報告。StockNews.com在週三的一份研究報告中對Nabriva治療公司的股票進行了報道。他們對該股的評級為“持有”。Northland Securities在1月6日星期五的一份研究報告中將Nabriva治療公司的股票評級從“跑贏大盤”下調至“表現不佳”。
到達Nabriva治療公司警報:Nabriva治療公司的價格表現
該公司的速動比率為1.40,流動比率為2.20,債務權益比為0.02。該公司的50日移動均線切入位在1.86美元,200日移動均線切入位在3.58美元。該公司市值為4,688萬美元,本益比為-0.08,貝塔係數為1.67。
納布裡瓦治療公司(納斯達克代碼:NBRV-GET評級)上一次公佈季度收益是在11月10日星期四。這家生物技術公司公佈了本季度每股收益(EPS)(4.21美元),低於普遍預期的(4.03美元)和(0.18美元)。納布裡瓦治療公司的淨利潤率為負133.25%,淨資產回報率為負120.02%。該公司本季度營收為915萬美元,高於分析師預期的1068萬美元。股票分析師平均預計,納布裡瓦治療公司本年度每股收益將達到17.37歐元。機構投資者看好Nabriva治療公司
一家機構投資者最近提高了對Nabriva治療公司股票的頭寸。根據復興科技有限公司提交給美國證券交易委員會(美國證券交易委員會)的最新Form 13F檔案,該公司在第二季度增持了納布裡瓦治療公司(Nabriva Treateutics Plc)的股票(Nabriva Treateutics Plc:NBRV-GET評級)102.1%。該機構投資者在此期間額外購買了402,144股後,持有這家生物技術公司的795,938股股票。在最近的報告期結束時,復興技術公司擁有Nabriva治療公司約0.13%的股份,價值14.5萬美元。機構投資者持有該公司0.23%的股票。
Nabriva治療公司簡介
(獲取評級)
Nabriva治療公司是一家生物製藥公司,從事治療嚴重感染的新型抗感染藥物的研究、開發和商業化。其產品線包括來福莫林、CONTEPO和BC-7013。該公司成立於2005年10月,總部設在愛爾蘭都柏林。
專題文章
- 免費獲取StockNews.com關於Nabriva治療公司(NBRV)的研究報告
- 雪佛龍以750億美元的股票回購取悅股東
- 電子商務的未來:分析和新數據
- 列維·施特勞斯非常適合收益型投資者
- 3只小盤股有很大的上漲空間
- 馬倫汽車:好消息、壞消息和醜陋的前景
接受Nabriva治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Nabriva治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧